Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 48, 2009, Pages 20330-20335

  Ehrlich, Elana S ^a   Wang, Tao ^a   Luo, Kun ^a   Xiao, Zuoxiang ^a   Niewiadomska, Anna Maria ^a   Martinez, Tara ^a   Xu, Wanping ^b   Neckers, Len ^b   Yu, Xiao Fang ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chaperone; Erbb2

Indexed keywords

CULLIN; CULLIN 5; ELONGIN B; ELONGIN C; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME CONFORMATION; ENZYME REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UBIQUITINATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE; CULLIN PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOPRECIPITATION; MICROSCOPY, FLUORESCENCE; MOLECULAR CHAPERONES; PROTEIN FOLDING; RECEPTOR, ERBB-2; RNA INTERFERENCE; UBIQUITINATION;

EID: 73949114912     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0810571106     Document Type: Article

References (35)

1. Dai C, Whitesell L, Rogers AB, Lindquist S (2007) Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130:1005-1018.
2. Solit DB, Rosen N (2006) Hsp90: A novel target for cancer therapy. Curr Top Med Chem 6:1205-1214.
3. Wegele H, Muller L, Buchner J (2004) Hsp70 and Hsp90-a relay team for protein folding. Rev Physiol Biochem Pharmacol 151:1-44.
4. Zhang H, Burrows F (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82:488-499.
5. Waterston RH, et al. (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420:520-562.
6. Citri A, Kochupurakkal BS, Yarden Y (2004) The achilles heel of ErbB-2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3:51-60.
7. Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8(4 Suppl):S55-S61.
8. Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6:9 -20.
9. Pintard L, Willems A, PeterM(2004) Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. EMBO J 23:1681-1687.
10. Deshaies RJ (1999) SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15:435-467.
11. Kamura T, et al. (2004) VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 18:3055-3065.
12. Mehle A, Thomas ER, Rajendran KS, Gabuzda D (2006) A zinc-binding region in Vif binds Cul5 and determines Cullin selection. J Biol Chem 281:17259-17265.
13. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF (2007) Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. Faseb J 21:217-222.
14. Xiao Z, et al. (2007) Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J Mol Biol 373:541-550.
15. Xiao Z, et al. (2006) Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349:290-299.
16. Blagosklonny MV (2002) Hsp-90-associated oncoproteins: Multiple targets of geldanamycin and its analogs. Leukemia 16:455-462.
17. Fay MJ, et al. (2003) Analysis of CUL-5 expression in breast epithelial cells, breast cancer cell lines, normal tissues and tumor tissues. Mol Cancer 2:40.
18. Yu X, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
19. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF (2004) Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 18:2867-2872.
20. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 18:2861-2866.
21. Stracker TH, Carson CT, Weitzman MD (2002) Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 418:348-352.
22. Luo K, et al. (2007) Adenovirus E4orf6 assembles with Cullin5-ElonginBElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53. Faseb J 21:1742-1750.
23. Harada JN, Shevchenko A, Shevchenko A, Pallas DC, Berk AJ (2002) Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol 76:9194-9206.
24. Querido E, et al. (2001) Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 15:3104-3117.
25. Baker A, Rohleder KJ, Hanakahi LA, Ketner G (2007) Adenovirus E4 34k and E1b 55k oncoproteins target host DNA ligase IV for proteasomal degradation. J Virol 81:7034-7040.
26. Young JC, Agashe VR, Siegers K, Hartl FU (2004) Pathways of chaperone mediated protein folding in the cytosol. Nat Rev Mol Cell Biol 5:781-791.
27. Prodromou C, et al. (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90:65-75.
28. Zhou P, et al. (2003) ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 278:13829-13837.
29. Xu W, et al. (2002) Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 99:12847-12852.
30. Safran M, Kaelin WG, Jr (2003) HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 111:779-783.
31. Lonergan KM, et al. (1998) Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18:732-741.
32. Maxwell PH, et al. (1999) The tumour suppressor protein VHL targets hypoxia inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
33. Isaacs JS, Jung YJ, Neckers L (2004) Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1alpha by modulating an Hsp90-dependent regulatory pathway. J Biol Chem 279:16128-16135.
34. Stebbins CE, Kaelin WG, Jr, Pavletich NP (1999) Structure of the VHLElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science 284:455-461.
35. Chen XP, et al. (2002) Pim serine/threonine kinases regulate the stability of Socs- 1 protein. Proc Natl Acad Sci USA 99:2175-2180.